Subscribe To

Price Alert Latest News Economic Calendar News

BCDA / BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study

Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure. Read More

Demo Live Account See Partner Details

Content Topics

Biocardia

BCDA

Dips

Flunking

Heart

Failure

Study

bcda

Stock

Posted: Sep 6 2023, 12:01

Author Name: Zacks Investment Research

BCDA News

By GlobeNewsWire
November 1, 2023

BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the tr

By Zacks Investment Research
October 12, 2023

BioCardia (BCDA) Up on Plans for Second Heart Failure Study

BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin

By Zacks Investment Research
September 6, 2023

BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study

Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the pr

By Proactive Investors
September 5, 2023

BioCardia shares slide on disappointing interim data from heart therapy trial

BioCardia shares fell more than 20% in pre-market trade on Tuesday after the biopharmaceutical firm revealed that its Phase 3 trial of CardiAMP cell t

By Zacks Investment Research
August 9, 2023

BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates

BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss

By GlobeNewsWire
May 3, 2023

BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the tre

By Seeking Alpha
March 29, 2023

BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Peter Altman - President & CEO David Mc

By Seeking Alpha
November 12, 2022

BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE IR Peter Altman

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.